Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Non Operating Income (2022 - 2025)

Summit Therapeutics' Non Operating Income history spans 4 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 30.16% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $14.8 million, up 10.99%, while the annual FY2025 figure was $14.8 million, 10.99% up from the prior year.
  • Non Operating Income reached $5.8 million in Q4 2025 per SMMT's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $16.1 million in Q4 2023 to a low of -$5.2 million in Q1 2023.
  • Average Non Operating Income over 4 years is $2.9 million, with a median of $2.6 million recorded in 2025.
  • The largest YoY upside for Non Operating Income was 689.95% in 2024 against a maximum downside of 72.55% in 2024.
  • A 4-year view of Non Operating Income shows it stood at $5.5 million in 2022, then skyrocketed by 194.35% to $16.1 million in 2023, then tumbled by 72.55% to $4.4 million in 2024, then soared by 30.16% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Non Operating Income are $5.8 million (Q4 2025), $2.4 million (Q3 2025), and $2.7 million (Q2 2025).